Suven Pharmaceuticals Ltd.
Snapshot View

517.85 +11.95 ▲2.4%

02 August 2021, 04:00:00 P.M.
Volume: 13,960

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.suvenpharm.com
Financial Indicators
Market Cap 12,878.44 Cr.
Earnings per share (EPS) 14.23 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 35.54 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 46.39 Trailing Twelve Months Ending 2021-03
Price to Book Value 10.91 Calculated using Price: 505.90
Dividend Yield 0.20 Period Ending 2020-03
No. of Shares Subscribed 25.46 Cr. 254,564,957 Shares
FaceValue 1
Company Profile

Suven Pharmaceuticals Limited, a company incorporated in November 2018, has become Wholly Owned Subsidiary of Suven Life Sciences Limited, effective February 2019. Suven Life Sciences Limited, post the Board meeting on February 5, 2019, announced demerger of Suven Life Sciences Limited into: Suven Life Sciences Limited, the demerged entity, to continue innovative research focused on Central Nervous System (CNS) disorders to meet huge unmet global medical needs. Suven Pharmaceuticals Limited, the resultant entity, to continue the CRAMS business operations. The Scheme of Arrangement has since been approved by the National Company Law Tribunal (NCT), Hyderabad bench vide its order on 6th January 2020.

Pursuant to the Scheme of Arrangement between Suven Life Sciences Limited (‘Demerged Company’), Suven Pharmaceuticals Limited (‘Resulting Company’) and their respective shareholders and creditors, duly approved by the National Company Law Tribunal (NCLT), Hyderabad Bench, vide its Order dated 06th January, 2020, the Demerged Undertaking (as defined in the Scheme) of the Demerged Company has been demerged from Suven Life Sciences Limited and the same has been transferred to and vested in Suven Pharmaceuticals Limited with effect from 1st October, 2018, being the Appointed Date fixed in the said Scheme of Arrangement.

The Scheme, has become operative from the Appointed Date i.e., 1st October, 2018, but has become effective on 9th January, 2020 being the date on which certified copies of the Order of the NCLT, Hyderabad Bench sanctioning the Scheme was filed with the Registrar of Companies, Hyderabad, Telangana, both by the Demerged Company and Resulting Company.

Business area of the company

The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.

Business segments

  • Pharmaceutical Solutions
  • Active Pharma ingredients
  • Intermediates
  • Formulations

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.36%
1 Week
+3.55%
1 Month
+5.74%
3 Month
-4.14%
6 Month
+9.44%
1 Year
+63.80%
2 Year
5 Year
2 years 2019-03 2020-03
Return on Equity (%) 18.92 37.80
Return on Capital Employed (%) 23.87 44.55
Return on Assets (%) 13.39 25.50

Balance Sheet View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 590 845
Non Curr. Liab. 35 128
Curr. Liab. 191 320
Minority Int.
Equity & Liab. 816 1,292
Non Curr. Assets 393 781
Curr. Assets 423 511
Misc. Exp. not W/O
Total Assets 816 1,292

Profit Loss View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 378 834
Other Income 1 18
Total Income 378 852
Total Expenditure -206 -449
PBIDT 172 403
Interest -3 -23
Depreciation -12 -24
Taxation -49 -88
Exceptional Items
PAT 109 269

Cash Flow View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 50 416
Cash Fr. Inv. -65 -422
Cash Fr. Finan. 26 6
Net Change 11 1
Cash & Cash Eqvt 11 12

Shareholding Pattern View Details

7 Qtrs 2019-11 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 100.00 60.00 60.00 60.00 60.00 60.00 60.00
Public 0.00 40.00 40.00 40.00 40.00 40.00 40.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 23 Jul 2021
Announcement under Regulation 30 (LODR)-Change in Directorate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) We wish to inform you that Board of Directors of the Company at its meeting held today i.e. July 23 2021 based on the recommendation of the Nomination and Remuneration Committee appointed Dr. Vajja Sambasiva Rao (DIN: 09233939) as additional and an Independent Director effective from July 23 2021 for a period of 5 (five) years subject to the approval of the shareholders in the ensuing Annual General Meeting of the Company.
The Board also approved investment of Rs 2.50 lakh (equivalent to 25% stake) by way of subscription in the new associate company - Rising Pharma Specialities Pvt. Ltd. under incorporation in India to take care of back office operations relating to Regulatory Accounting Information and Technology and other Logistic Services for Rising Pharma Holdings Inc. USA.
Tue, 20 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
118190
Name of the Signatory :- K HANUMANTHA RAO
Designation :- Company Secretary and Compliance Officer
Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Suven Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Fri, 30 Jul 2021
High Delivery Percentage High Delivery Percentage
Close Crossing Last Week High Close Crossing Last Week High
Close Within 52 Week High Zone Close Within 52 Week High Zone
S Close Above Last Week High
MFI Trending Up MFI Trending Up

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.45 +0.1%
Divi's Laboratories Ltd. 129,702.64 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,701.80 -0.2%
Cipla Ltd. 74,235.31 921.80 +0.2%
Cadila Healthcare Ltd. 59,986.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,049.00 +0.4%
Aurobindo Pharma Ltd. 53,701.27 918.00 +0.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 30.87 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 918.00 +0.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 4.05 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 918.00 +0.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 918.00 +0.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 918.00 +0.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 918.00 +0.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 918.00 +0.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 918.00 +0.1%